title: Cost-effectiveness analysis of switching from intravenous to oral administration of antibiotics in elderly patients.
abstract: OBJECTIVE
  The aim of the introduced work was to evaluate pharmacoeconomic advantages of timely switching from intravenous to oral administration of antibiotics (ATB).
  
  
  METHODS
  The evaluated group was selected out of 2870 patients, who were hospitalised at the Clinic of Geriatric Medicine of the Faculty of Medicine of Comenius University in Bratislava from January 1st 1999 to December 31st 2001. In our retrospective study we analysed 96 patients with community-acquired pneumonia successfully treated by ATB. In 43 of them ATB were given intravenously and in 53 the therapy was switched, i.e. the intravenous administration was used at the beginning and oral administration when the condition improved. We applied a cost-effectiveness analysis to the pharmacoeconomic evaluation. The cost-effectiveness coefficient was calculated as the ratio of ATB price (Slovak Crowns) to the effectiveness criterion (number of asymptomatic days in month).
  
  
  RESULTS
  According to the cost-effectiveness coefficient, the switch therapy was significantly less expensive in all evaluated ATB (except for pefloxacin) in comparison with intravenous administration: ampicillin-sulbactam 93.9 vs 168.1; cefuroxime 90.0 vs 123.3; amoxicillin-clavulanate 74.0 vs 116.3; ciprofloxacin 31.7 vs 54.1.
  
  
  CONCLUSIONS
  A timely switching from intravenous to oral administration of ATB in a suitable patient is an effective way to save financial resources. (Tab. 5, Ref: 21.)
authors.affiliation: Department of Pharmacology, Faculty of Medicine, Comenius University, Bratislava, Clinic of Geriatric Medicine, Academic Derer's University Hospital, Bratislava, Slovakia. wawruch@hotmail.com
authors.forename: M
authors.initials: M
authors.lastname: Wawruch
authors.forename: L
authors.initials: L
authors.lastname: Bozekova
authors.forename: S
authors.initials: S
authors.lastname: Krcmery
authors.forename: K
authors.initials: K
authors.lastname: Kozlikova
authors.forename: V
authors.initials: V
authors.lastname: Foltan
authors.forename: J
authors.initials: J
authors.lastname: Galatova
authors.forename: M
authors.initials: M
authors.lastname: Lassanova
authors.forename: M
authors.initials: M
authors.lastname: Kriska
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000191:economics*; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D011014:Pneumonia / Q000188:drug therapy
chemical_list: D000900:Anti-Bacterial Agents